Nutra Pharma Corp (NPHC) 0.0029 $NPHC
Nutra Pharma Announces Nyloxin(R) Distribution Plans for Canada
Marketwired - Thu May 14, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged the Nature's Clinic to begin the process of regulatory approval of the Company's Over-the-Counter pain drug, Nyloxin(R) for marketing and distribution in Canada.
Nutra Pharma Announces Nyloxin(R) Acceptance by Chinese Medical Authority - CPAM
Marketwired - Thu Apr 30, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have received notification of the acceptance of Nyloxin(R) by the China International Exchange and Promotive Association for Medical and Healthcare (CPAM). This process was successfully conducted by the Vancouver Commodities Group (VCG) that had been hired by Nutra Pharma to begin the process of identifying and vetting potential distributors in China for the Company's Over-the-Counter pain drug, Nyloxin(R).
Nutra Pharma Announces Nyloxin(R) Distribution Plans for China
Marketwired - Wed Apr 22, 7:31AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged the Vancouver Commodities Group (VCG) to begin the process of identifying and vetting potential distributors in China for the Company's Over-the-Counter pain drug, Nyloxin(R).
Nutra Pharma Provides Updates on Marketing and Distribution of Nyloxin(R) to India
Marketwired - Wed Apr 15, 7:30AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is providing an update regarding their plan to market their over-the-counter (OTC) pain reliever, Nyloxin(R) through S.Zhaveri Pharmakem for distribution throughout India. Nutra Pharma previously announced that they had shipped their initial test orders of Nyloxin(R) in February to ensure Customs clearance before escalating order sizes and frequency. Nutra Pharma management has been working in Mumbai this week to finalize their plans for the national rollout of Nyloxin.
Nutra Pharma Announces Distribution of Nyloxin(R) to India
Marketwired - Thu Feb 05, 7:30AM CST
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have shipped their initial test orders of their Over-the-Counter pain drug, Nyloxin(R), to S.Zhaveri Pharmakem for distribution throughout India.
Nutra Pharma Announces Addition of Keith Gordon, DVM to the Company's Medical Advisory Board
Marketwired - Tue Jan 20, 7:30AM CST
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have added Keith Gordon, DVM as their first Veterinarian to join the Company's Medical Advisory Board. The addition of Dr. Gordon comes just a few weeks after the successful launch of Nutra Pharma's newest product, Pet Pain-Away for the treatment of chronic pain in companion animals.
Nutra Pharma Announces Manufacturing Release of Pet Pain-Away and Delivery of Initial Orders
Marketwired - Wed Dec 17, 7:30AM CST
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), announced today that they have received their first manufacturing run of their homeopathic treatment for chronic pain in companion animals, Pet Pain-Away(TM). The Company also announced that they have begun shipping and many distributors have already received their first orders.
Nutra Pharma Letter to Shareholders
Marketwired - Thu Dec 04, 7:31AM CST
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Shareholder Letter on the Company's website.
Nutra Pharma Announces Laboratory Recertification and Manufacturing Updates
Marketwired - Wed Nov 12, 7:32AM CST
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing the recertification of their Plantation, Florida laboratory facilities. This includes manufacturing, research and production space as well as a clean room module. The recertification allows for the continuing production of their over-the-counter (OTC) pain reliever, Nyloxin(R) and their newest product, Pet Pain-Away; a homeopathic treatment for pain in companion animals. The primary purpose of the laboratory updates, calibrations and certification is to allow the company to re-engage in their clinical platform and to begin eventual trials in their drug pipeline with therapeutic agents for MS, HIV and AMN.
Nutra Pharma Retains BUYINS.NET to Surveil Short Sellers and Market-Makers
Marketwire - Thu Aug 21, 7:30AM CDT
Nutra Pharma Corp (OTC: NPHC)
BUYINS.NET Issues Nutra Pharma (NPHC) SqueezeTrigger Report
M2 - Thu Aug 21, 7:02AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Nutra Pharma Corp (OTC: NPHC) after releasing the latest short sale data through August 18, 2014. The total aggregate number of shares shorted since August 2009 is approximately 547 million shares. Approximately 32.11% of daily trading volume is short selling. The SqueezeTrigger price for all NPHC shares shorted is $.08. A short squeeze is expected to begin when NPHC closes above the $.08 SqueezeTrigger price.
Nutra Pharma Provides Nyloxin(R) Marketing Updates
Marketwire - Tue Aug 19, 7:02AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing updates to the marketing plan for their over-the-counter (OTC) pain reliever, Nyloxin(R). Nutra Pharma previously announced a commercial campaign that began at the end of June 2014. Additional commercials are being produced as well as ongoing support on a weekly radio campaign.
Nutra Pharma Analyst Report by Small Cap Traders and Issued by BrokerBank Securities, Inc.
PR Newswire - Tue Aug 19, 6:00AM CDT
Nutra Pharma Corp. (OTCBB: NPHC) has experienced recurring, significant losses from operations, and has an accumulated deficit of $43,512,705 at June 30, 2014. In addition, it had respective working capital and stockholders' deficits at June 30, 2014 of $3,967,164 and $3,964,165 respectively. There is a substantial doubt regarding Nutra Pharma's ability to continue as a going concern which is contingent upon its ability to secure additional financing, increase ownership equity and attain profitable operation. However, an increase in sales of Nyloxin® during the six month period ended June 2014, along with the steady annual growth rate in the global pain management drug market, can bring relief to offset losses.
Nutra Pharma Announces Infrastructure Improvements to Handle Increased Sales
GlobeNewswire - Thu Jul 24, 7:00AM CDT
Nutra Pharma Corp. (OTCPink:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that they are in the process of completing critical capital improvements to their warehouse and fulfillment center in order to meet increased demand and shipments of their over-the-counter (OTC) pain reliever, Nyloxin(R). These improvements include: new rack systems throughout the facility, the purchase of a forklift, new management software as well as hiring additional staff.
Myasthenia Gravis - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z232kc/myasthenia_gravis) has announced the addition of the "Myasthenia Gravis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myasthenia Gravis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myasthenia Gravis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - GlaxoSmithKline plc - Grifols, S.A. - Astellas Pharma Inc. - Nutra Pharma Corporation - Alexion Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Cytokinetics, Inc. - HanAll Biopharma Co., Ltd. - CuraVac, Inc. - Biokine Therapeutics Ltd. - Toleranzia AB For more information visit http://www.researchandmarkets.com/research/z2...nia_gravis
CYTK: 5.96 (-0.06), ALXN: 160.56 (-1.13), GSK: 44.77 (-0.22)
Emerging Market Companies and Investor Updates Provided by BrokerBank Securities, Inc.
PR Newswire - Thu Jun 26, 6:00AM CDT
NYBD Holding, Inc. (OTCBB: NYBD) has filed for a name change and it has been accepted. The company will now be trading under (AQUA), will be named Pleasant Kids, Inc. and the company is expecting the name and symbol change to take affect within the next few business days.
Nutra Pharma reports airing of OTC Pain Reliever Nyloxin commercials on television
M2 - Thu Jun 26, 5:04AM CDT
Biotechnology company Nutra Pharma (OTC:NPHC) disclosed on Wednesday that MyNyloxin.com has begun airing television commercials of its OTC Pain Reliever Nyloxin to help grow sales and increase public awareness.
Nutra Pharma Announces Nyloxin Television Commercial Rollout
Marketwire - Wed Jun 25, 9:10AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin.com, a company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), has begun airing television commercials as of Monday, June 23rd. The advertisements focus on the benefits of Nyloxin(R). The first contract has already begun and includes over 30,000 spots to run throughout the Southeast Region from Comcast and AT&T U-Verse Cable providers. The ads are scheduled to run on the following channels: GOLF, LMN, CNBC, FOXN, MSNBC, NBCS, ESPN, ESPN2, TNT, FOXS, TWC, CNN, HALL, HGTV, TLC, HLN and LIFE. Starting June 30, the commercials will begin airing in the New York and New Jersey markets with a rollout to the national stage in the coming weeks.
Nutra Pharma Announces Completion of Commercials by MyNyloxin.com
Marketwire - Wed Jun 25, 8:25AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin.com, a new company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel has completed their work on a series of commercials to start airing in the month of June. The advertisements focus on the benefits of Nyloxin(R) and include 30 second, 60 second and 120 second spots.
Nutra Pharma Announces Nyloxin(R) Distribution Plans for Canada
Marketwired - Thu May 14, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged the Nature's Clinic to begin the process of regulatory approval of the Company's Over-the-Counter pain drug, Nyloxin(R) for marketing and distribution in Canada.
Nutra Pharma Announces Nyloxin(R) Acceptance by Chinese Medical Authority - CPAM
Marketwired - Thu Apr 30, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have received notification of the acceptance of Nyloxin(R) by the China International Exchange and Promotive Association for Medical and Healthcare (CPAM). This process was successfully conducted by the Vancouver Commodities Group (VCG) that had been hired by Nutra Pharma to begin the process of identifying and vetting potential distributors in China for the Company's Over-the-Counter pain drug, Nyloxin(R).
Nutra Pharma Announces Nyloxin(R) Distribution Plans for China
Marketwired - Wed Apr 22, 7:31AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged the Vancouver Commodities Group (VCG) to begin the process of identifying and vetting potential distributors in China for the Company's Over-the-Counter pain drug, Nyloxin(R).
Nutra Pharma Provides Updates on Marketing and Distribution of Nyloxin(R) to India
Marketwired - Wed Apr 15, 7:30AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is providing an update regarding their plan to market their over-the-counter (OTC) pain reliever, Nyloxin(R) through S.Zhaveri Pharmakem for distribution throughout India. Nutra Pharma previously announced that they had shipped their initial test orders of Nyloxin(R) in February to ensure Customs clearance before escalating order sizes and frequency. Nutra Pharma management has been working in Mumbai this week to finalize their plans for the national rollout of Nyloxin.
Nutra Pharma Announces Distribution of Nyloxin(R) to India
Marketwired - Thu Feb 05, 7:30AM CST
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have shipped their initial test orders of their Over-the-Counter pain drug, Nyloxin(R), to S.Zhaveri Pharmakem for distribution throughout India.
Nutra Pharma Announces Addition of Keith Gordon, DVM to the Company's Medical Advisory Board
Marketwired - Tue Jan 20, 7:30AM CST
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have added Keith Gordon, DVM as their first Veterinarian to join the Company's Medical Advisory Board. The addition of Dr. Gordon comes just a few weeks after the successful launch of Nutra Pharma's newest product, Pet Pain-Away for the treatment of chronic pain in companion animals.
Nutra Pharma Announces Manufacturing Release of Pet Pain-Away and Delivery of Initial Orders
Marketwired - Wed Dec 17, 7:30AM CST
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), announced today that they have received their first manufacturing run of their homeopathic treatment for chronic pain in companion animals, Pet Pain-Away(TM). The Company also announced that they have begun shipping and many distributors have already received their first orders.
Nutra Pharma Letter to Shareholders
Marketwired - Thu Dec 04, 7:31AM CST
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Shareholder Letter on the Company's website.
Nutra Pharma Announces Laboratory Recertification and Manufacturing Updates
Marketwired - Wed Nov 12, 7:32AM CST
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing the recertification of their Plantation, Florida laboratory facilities. This includes manufacturing, research and production space as well as a clean room module. The recertification allows for the continuing production of their over-the-counter (OTC) pain reliever, Nyloxin(R) and their newest product, Pet Pain-Away; a homeopathic treatment for pain in companion animals. The primary purpose of the laboratory updates, calibrations and certification is to allow the company to re-engage in their clinical platform and to begin eventual trials in their drug pipeline with therapeutic agents for MS, HIV and AMN.
Nutra Pharma Retains BUYINS.NET to Surveil Short Sellers and Market-Makers
Marketwire - Thu Aug 21, 7:30AM CDT
Nutra Pharma Corp (OTC: NPHC)
BUYINS.NET Issues Nutra Pharma (NPHC) SqueezeTrigger Report
M2 - Thu Aug 21, 7:02AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Nutra Pharma Corp (OTC: NPHC) after releasing the latest short sale data through August 18, 2014. The total aggregate number of shares shorted since August 2009 is approximately 547 million shares. Approximately 32.11% of daily trading volume is short selling. The SqueezeTrigger price for all NPHC shares shorted is $.08. A short squeeze is expected to begin when NPHC closes above the $.08 SqueezeTrigger price.
Nutra Pharma Provides Nyloxin(R) Marketing Updates
Marketwire - Tue Aug 19, 7:02AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing updates to the marketing plan for their over-the-counter (OTC) pain reliever, Nyloxin(R). Nutra Pharma previously announced a commercial campaign that began at the end of June 2014. Additional commercials are being produced as well as ongoing support on a weekly radio campaign.
Nutra Pharma Analyst Report by Small Cap Traders and Issued by BrokerBank Securities, Inc.
PR Newswire - Tue Aug 19, 6:00AM CDT
Nutra Pharma Corp. (OTCBB: NPHC) has experienced recurring, significant losses from operations, and has an accumulated deficit of $43,512,705 at June 30, 2014. In addition, it had respective working capital and stockholders' deficits at June 30, 2014 of $3,967,164 and $3,964,165 respectively. There is a substantial doubt regarding Nutra Pharma's ability to continue as a going concern which is contingent upon its ability to secure additional financing, increase ownership equity and attain profitable operation. However, an increase in sales of Nyloxin® during the six month period ended June 2014, along with the steady annual growth rate in the global pain management drug market, can bring relief to offset losses.
Nutra Pharma Announces Infrastructure Improvements to Handle Increased Sales
GlobeNewswire - Thu Jul 24, 7:00AM CDT
Nutra Pharma Corp. (OTCPink:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that they are in the process of completing critical capital improvements to their warehouse and fulfillment center in order to meet increased demand and shipments of their over-the-counter (OTC) pain reliever, Nyloxin(R). These improvements include: new rack systems throughout the facility, the purchase of a forklift, new management software as well as hiring additional staff.
Myasthenia Gravis - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z232kc/myasthenia_gravis) has announced the addition of the "Myasthenia Gravis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myasthenia Gravis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myasthenia Gravis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - GlaxoSmithKline plc - Grifols, S.A. - Astellas Pharma Inc. - Nutra Pharma Corporation - Alexion Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Cytokinetics, Inc. - HanAll Biopharma Co., Ltd. - CuraVac, Inc. - Biokine Therapeutics Ltd. - Toleranzia AB For more information visit http://www.researchandmarkets.com/research/z2...nia_gravis
CYTK: 5.96 (-0.06), ALXN: 160.56 (-1.13), GSK: 44.77 (-0.22)
Emerging Market Companies and Investor Updates Provided by BrokerBank Securities, Inc.
PR Newswire - Thu Jun 26, 6:00AM CDT
NYBD Holding, Inc. (OTCBB: NYBD) has filed for a name change and it has been accepted. The company will now be trading under (AQUA), will be named Pleasant Kids, Inc. and the company is expecting the name and symbol change to take affect within the next few business days.
Nutra Pharma reports airing of OTC Pain Reliever Nyloxin commercials on television
M2 - Thu Jun 26, 5:04AM CDT
Biotechnology company Nutra Pharma (OTC:NPHC) disclosed on Wednesday that MyNyloxin.com has begun airing television commercials of its OTC Pain Reliever Nyloxin to help grow sales and increase public awareness.
Nutra Pharma Announces Nyloxin Television Commercial Rollout
Marketwire - Wed Jun 25, 9:10AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin.com, a company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), has begun airing television commercials as of Monday, June 23rd. The advertisements focus on the benefits of Nyloxin(R). The first contract has already begun and includes over 30,000 spots to run throughout the Southeast Region from Comcast and AT&T U-Verse Cable providers. The ads are scheduled to run on the following channels: GOLF, LMN, CNBC, FOXN, MSNBC, NBCS, ESPN, ESPN2, TNT, FOXS, TWC, CNN, HALL, HGTV, TLC, HLN and LIFE. Starting June 30, the commercials will begin airing in the New York and New Jersey markets with a rollout to the national stage in the coming weeks.
Nutra Pharma Announces Completion of Commercials by MyNyloxin.com
Marketwire - Wed Jun 25, 8:25AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin.com, a new company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel has completed their work on a series of commercials to start airing in the month of June. The advertisements focus on the benefits of Nyloxin(R) and include 30 second, 60 second and 120 second spots.
